[Abciximab (c7E3)--a new monoclonal antibody--from the pharmaco-economic viewpoint. Initial reports from the literature].
Sturm
C
C
Apotheke Klinikum Innenstads, Ludwig-Maximiliant-Universität München.
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000191:economics*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics*; D003328:Coronary Thrombosis / Q000191:economics* / Q000628:therapy; D003362:Cost-Benefit Analysis; D004311:Double-Blind Method; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000191:economics*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000191:economics*; D011446:Prospective Studies; D016896:Treatment Outcome; D014481:United States
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab